Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 5;19(2):2245727. doi: 10.1080/21645515.2023.2245727

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Pfizer Inc. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 5. — Serotype-specific OPA GMTs for the cPCV7 serotypes at (a) 1 month after Dose 3 (Dose 3 evaluable immunogenicity population), (b) 1 month after Dose 4 (Dose 4 evaluable immunogenicity population), and (c) 1 month after the Supplemental Dose (Supplemental Dose all-available immunogenicity population). Doses 3 and 4 refer to doses of cPCV7 administered in the cPCV7 Coadministered and cPCV7 Separated groups or doses of PCV13 administered in the PCV13 Control group. The Supplemental Dose refers to the cPCV7 dose given in the PCV13 Control group. OPA titers were determined based on serum from a randomly selected subset of participants. Error bars display the upper and lower bounds of the 2-sided 95% CIs for GMTs calculated based on the Student t distribution. Assay results below the LLOQ were set to 0.5 × LLOQ in the GMT calculations. At 1 month after Dose 3, n = 38‒46 for the cPCV7 Coadministered group, n = 38‒45 for the cPCV7 Separated group, and n = 40‒44 for the PCV13 Control group. At 1 month after Dose 4, n = 24‒28 for the cPCV7 Coadministered group, n = 25‒28 for the cPCV7 Separated group, and n = 24‒29 for the PCV13 Control group. At 1 month after the Supplemental Dose, n = 21‒26 for the PCV13 Control group. cPCV7 = complementary 7-valent pneumococcal conjugate vaccine; GMT = geometric mean titer; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity; PCV13 = 13-valent pneumococcal conjugate vaccine.